- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00752024
Stereotactic Aspiration and Thrombolysis of Intracerebral Hemorrhage: a Prospective Controlled Study (SATIH)
Stereotactic Aspiration and Thrombolysis of Intracerebral Hemorrhage: a Prospective Controlled Study(SATIH)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The stereotactic computed tomographic-guided aspiration and drainage is one of the best choices in the treatment of a large-scale deep supratentorial intracerebral hematoma. It uses hardware access technology, in a relatively short time to enter the hematoma center, with suction liquefaction technology. It has the advantage of a higher clearance rate of the hematoma, simple convenience, small trauma and low-cost. We carry on the suitable improvement in this technology's foundation in view of its deficiency, the introduction of the concept of the individual, will further reduce the rate of bleeding and mortality, improve survival, such as long-term quality of life.
We will adopt scales such as the rate of rebleeding, mortality, complication,NIHSS, MRS, BI, GOS scale to analysis and evaluating efficacy and safety of this technology and conservative treatment in the treatment of HICH.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Hubei
-
Wuhan, Hubei, China, 430030
- Department of Neurology of Tongji Hospital, Huazhong University of Science and Technology
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- CT diagnosis of spontaneous supratentorial intracerebral hemorrhage, the amount of bleeding more than 50 ml, and had neurological signs
- All income groups the incidence of medical records to be random, the time should be < 69 hours to ensure that within 72 hours of the onset of the operation
- To be random, former GCS score > = 5 points
- Systolic blood pressure <= 200 mmHg, mean arterial pressure <= 150 mmHg (if higher than this value, but as corresponding to this standard can be dealt with the group, and only reached the standard before they can ask for random)
- Fasting plasma glucose <= 11.1 mmol / L (if higher than this value, but as corresponding to this standard can be dealt with the group, and only reached the standard before they can ask for random)
- Patients aged 18 to 80-year-old.
- Based on China's relevant laws, the patient himself or family members (only in patients with the loss of his ability to judge the acts of circumstances) agreed to participate in this study, a good compliance, to fully comply with random, in accordance with the decision by the treatment, patients himself Or family members must sign informed consent moreover.
- Patients themselves or their families (only in patients with the loss of his ability to judge the acts of circumstances) have willingness and ability to follow the research program, data collection and preservation of history and follow-up process of informed consent.
Exclusion Criteria:
- Patients clotting mechanisms are obstacles or having the experience of the use of anticoagulant drug (PT> 15s, APTT> 40s, INR> 1.4, platelet count <100 × 10 9 / L).
- Cerebral hernia formed more than two hours
- The merger of other serious system failure (heart, liver and kidney, etc.) or a variety of end-stage disease with cerebral hematoma (such as renal failure late cerebral hemorrhage, blood disease with cerebral hemorrhage)
- Prior to the onset of a variety of reasons for the defect or neurological movement disorder
- A clear cause of cerebral hemorrhage such as intracranial aneurysm, or dynamic
- such as a venous malformation
- Intracranial or serious systemic infection
- Marked cognitive impairment or mental abnormality
- Other such as pregnancy, cancer
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 1
To position haematoma's location, drills several millimeter holes in the localization point of puncture, then insert the drainage tube to inhale haematoma, gives the filament resolver interrupted for liquefication drainage afterward.
|
YL-1 type of intracranial hematoma puncture needle(Pat. NO.is ZL:93244252•8) was originated by Beijing WanTeFu Medical Apparatus Co.Ltd in 1997. With integration of needle and bur drill it is designed as hard tunnel.By the technique of skull self-holding, the puncture needle can being fixed in the target of haematoma for several days.This technique is convenient, simple and safe. To position haematoma's location, drills 3 millimeter holes in the localization point of puncture, then insert the drainage tube to inhale haematoma, gives the filament resolver interrupted for liquefication drainage afterward.
Other Names:
|
Active Comparator: 2
In the treatment, under the convention we use the dehydrator for patients, the ultra early patient may use anti-filament medicinal preparation 6- amino-caproic acid 6-12g/d, intravenous drip, the period of revolution does not surpass for 24 hours, then just right for the illness treatment.
|
In the treatment, under the convention we use the dehydrator for patients, the ultra early patient may use anti-filament medicinal preparation 6- amino-caproic acid 6-12g/d, intravenous drip, the period of revolution does not surpass for 24 hours, then just right for the illness treatment.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The rate of rebleeding and mortality, Glasgow Outcome Scale for prognosis
Time Frame: duration of 14 days after operation(rebleeding), duration of hospital stay(mortality), 180 days after onset(mortality and GOS)
|
duration of 14 days after operation(rebleeding), duration of hospital stay(mortality), 180 days after onset(mortality and GOS)
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Nation of Health Stroke Scale Score , modified Rankin Scale, Barthel Index complications
Time Frame: the moment of admission and post operation(NIHSS), 14 days after admission(NIHSS,MRS), duration of hospital stay(complications), 180 days after onset(BI, MRS)
|
the moment of admission and post operation(NIHSS), 14 days after admission(NIHSS,MRS), duration of hospital stay(complications), 180 days after onset(BI, MRS)
|
Collaborators and Investigators
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2006AA301B50-1
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypertensive Intracerebral Hemorrhage
-
Tongji HospitalUnknown
-
Huazhong University of Science and TechnologyUnknownHypertensive Intracerebral HemorrhageChina
-
Shanghai Changzheng HospitalXiangya Hospital of Central South University; LanZhou University; Peking Union... and other collaboratorsNot yet recruitingHypertensive Intracerebral Hemorrhage
-
Shanghai Changzheng HospitalThe First Affiliated Hospital of Nanchang University; Peking Union Medical... and other collaboratorsNot yet recruitingHypertensive Intracerebral HemorrhageChina
-
First Affiliated Hospital, Sun Yat-Sen UniversityJiangsu Simcere Pharmaceutical Co., Ltd.Not yet recruitingIntracerebral Hemorrhage
-
Wake Forest University Health SciencesActive, not recruitingStroke Hemorrhagic | Intracerebral Hemorrhage | Cerebral Edema | Intracerebral Hemorrhage, Hypertensive | Intracerebral Hemorrhage IntraparenchymalUnited States
-
University of RijekaCompletedBrain Injuries | Intraventricular Hemorrhage | Hypertensive Intracerebral Hemorrhage
-
Guangzhou University of Traditional Chinese MedicineLiaocheng People's Hospital; Lianjiang people's Hospital; Shenyang Second Hospital... and other collaboratorsUnknownTraditional Chinese Medicine | Intracerebral Hemorrhage, HypertensiveChina
-
The First People's Hospital of JingzhouCompletedHematoma Absorption and Neurological Function Recovery
-
Chinese PLA General HospitalThe First Affiliated Hospital of Nanchang University; First Affiliated Hospital... and other collaboratorsCompletedIntracranial Hemorrhage, HypertensiveChina
Clinical Trials on YL-1 type of intracranial hematoma puncture needle
-
Tongji HospitalUnknown
-
Beijing Tiantan HospitalRecruitingChronic Subdural HematomaChina
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedRenal Pelvis and Ureter Urothelial CarcinomaUnited States
-
St. Olavs HospitalUllevaal University Hospital; University Hospital of North Norway; Norwegian... and other collaboratorsActive, not recruiting
-
Daiichi Sankyo, Inc.Completed
-
Joseph Baar, MD, PhDCompletedBreast Cancer | Metastatic Breast CancerUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)RecruitingRefractory Melanoma | HLA-A2 Positive Cells PresentUnited States
-
Children's Oncology GroupRecruitingRecurrent Acute Lymphoblastic Leukemia | Refractory Acute Lymphoblastic Leukemia | Recurrent Mixed Phenotype Acute Leukemia | Refractory Mixed Phenotype Acute Leukemia | Refractory Acute Leukemia of Ambiguous Lineage | Recurrent Acute Leukemia of Ambiguous Lineage | Recurrent Acute Myeloid Leukemia... and other conditionsUnited States
-
University of UtahBoston University; University of Pennsylvania; Northwestern University; Columbia... and other collaboratorsCompleted
-
Shandong Cancer Hospital and InstituteUnknown